Modular siRNA Delivery with Lipidated Secondary Antibody Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for delivering siRNA therapeutics to tissues outside the liver are inefficient and require significant optimization for each cell type, leading to high development costs and limited clinical translation of targeted siRNA delivery.
Innovation Solution
A modular platform using lipidated secondary antibodies non-covalently attached to lipidated peptides, allowing flexible targeting of diverse cell types by substituting antibodies without the need for extensive optimization, enabling specific siRNA uptake and gene knockdown.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemical conjugation methods are used to attach antibodies to delivery carriers, then targeted delivery can be achieved, but the process requires extensive optimization for each cell type and has low efficiency
Solution Approach 1:
The patent introduces a modular platform consisting of a delivery carrier, a linker component, and an antibody component that can be assembled without extensive optimization. The linker acts as an intermediary that standardizes the connection between the carrier and antibody, eliminating the need for custom chemical conjugation protocols for each cell type while maintaining targeted delivery efficiency.
Solution Approach 2:
The patent creates a universal delivery platform where the same core carrier and linker components can be used with different antibodies to target multiple cell types. This modular design allows the system to be adapted to various therapeutic applications without requiring re-optimization of the fundamental delivery mechanism, achieving both reliability and ease of use.
2Reliability
If lipid-based nanoparticles are used for siRNA delivery, then liver gene knockdown is achieved, but delivery to tissues outside the liver is inefficient
Solution Approach 1:
The patent develops a universal nanoparticle platform that maintains the proven liver delivery capability of lipid-based nanoparticles while adding the versatility to target extrahepatic tissues. The modular antibody component allows the same carrier to be adapted for different tissue targets, achieving both reliability in gene knockdown and adaptability across multiple tissue types.
Solution Approach 2:
The patent segments the delivery system into distinct functional modules: the lipid-based nanoparticle core for siRNA delivery and gene knockdown, and a separate antibody component for tissue-specific targeting. This segmentation allows the core delivery mechanism to be optimized for reliability while the antibody module provides versatility for different tissue targets.
3Reliability
If antibody fusion proteins are used for targeted siRNA delivery, then cell-specific uptake is achieved, but development costs are high due to extensive optimization requirements
Solution Approach 1:
The patent creates a universal platform where the core delivery mechanism and linker components can be reused across different therapeutic targets. This eliminates the need to develop and optimize separate antibody fusion proteins for each cell type, significantly reducing development costs while maintaining cell-specific uptake capability through the modular antibody component.
Solution Approach 2:
The patent uses a standardized modular design that can be copied and adapted for different targets without requiring de novo optimization. The proven carrier and linker components serve as templates that can be replicated for various therapeutic applications, reducing development time and cost while maintaining reliable cell-specific delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The platform achieves exquisitely specific uptake and knockdown in various cell types, including difficult-to-transfect cells, as demonstrated by targeted siRNA delivery to Ly6C+ monocytes and CD4+ cells, reducing bystander toxicity and ameliorating inflammatory bowel disease symptoms, and prolonging survival in cancer models.
Implementation Method 1
a lipidated polypeptide non-covalently attached to an outer surface of a particle via the lipidated portion of the lipidated polypeptide
Data Source
Figure 1A~1I
Figure 1J
Figure 2A~2C
AI summary
A lipidated secondary antibody is disclosed. Particles comprising same are also disclosed.